Annals of Allergy, Asthma & Immunology · Nov 2026

A RARE REACTION TO A NOVEL THERAPY: CAGRILINTIDE-INDUCED ANAPHYLAXIS

By Deendyal A, Wild L

Introduction Cagrilintide is a long-acting amylin receptor agonist being studied for the treatment of obesity and type 2 diabetes. Clinical trials have shown significant weight loss, and severe hypersensitivity reactions have not been reported. We present a case of suspected cagrilintide-induced anaphylaxis supported by positive specific IgE skin testing. Case Description A 35-year-old man with anxiety and eosinophilic esophagitis was evaluated after an immediate allergic reaction. Thirty minutes after self-administering subcutaneous GHK-copper peptide, glutathione, retatrutide, and cagrilintide, he developed flushing, diffuse pruritus, urticaria, lip angioedema, shaking, and chest tightness. He was treated in the emergency department with corticosteroids and antihistamines, and his symptoms resolved. He had previously tolerated GHK-copper peptide, glutathione, and retatrutide. After the event, he restarted each of these medications without recurrence of symptoms. Cagrilintide was the only medication not reintroduced. Skin prick testing to cagrilintide was positive with appropriate controls. Testing of the same preparation in a healthy control was negative, making an irritant response less likely. Taken together, the clinical history, selective re-challenge, and skin testing suggested cagrilintide as the likely culprit. Discussion This case suggests cagrilintide can cause immediate hypersensitivity and anaphylaxis. The diagnosis was supported by the timing of symptom onset, positive skin prick testing, and tolerance of the other injected medications after re-challenge. As cagrilintide becomes more widely used, clinicians should be aware of this rare but potentially serious adverse reaction.

doi.org/10.1016/j.anai.2026.09.386Interventions

AgingResearch.News